Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease

Koji Tamada, Hideto Tamura, Dallas Flies, Yang Xin Fu, Esteban Celis, Larry R. Pease, Bruce R. Blazar, Lieping Chen

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor-Ig (LTβR-Ig) inhibits the cytotoxic T lymphocyte (CTL) response to host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in a B6 to BDF1 mouse model. Here, we demonstrate that infusion of an mAb against CD40 ligand (CD40L) further increases the efficacy of LTβR-Ig, leading to complete prevention of GVHD. We further demonstrate that alloantigen-specific CTLs become anergic upon rapid expansion, and persist in the tolerized mice asa result of costimulatory blockade. Transfer of anergic CTLs to secondary F1 mice fails to induce GVHD despite the fact that anergic CTLs can be stimulated to proliferate in vitro by antigens and cytokines. Our study provides a potential new approach for the prevention of lethal GVHD.

Original languageEnglish (US)
Pages (from-to)549-557
Number of pages9
JournalJournal of Clinical Investigation
Volume109
Issue number4
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Graft vs Host Disease
T-Lymphocytes
Light
Lymphotoxin-alpha
CD40 Ligand
Isoantigens
Cytotoxic T-Lymphocytes
Cytokines
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. / Tamada, Koji; Tamura, Hideto; Flies, Dallas; Fu, Yang Xin; Celis, Esteban; Pease, Larry R.; Blazar, Bruce R.; Chen, Lieping.

In: Journal of Clinical Investigation, Vol. 109, No. 4, 01.01.2002, p. 549-557.

Research output: Contribution to journalArticle

Tamada, Koji ; Tamura, Hideto ; Flies, Dallas ; Fu, Yang Xin ; Celis, Esteban ; Pease, Larry R. ; Blazar, Bruce R. ; Chen, Lieping. / Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. In: Journal of Clinical Investigation. 2002 ; Vol. 109, No. 4. pp. 549-557.
@article{df453a5fd0d5493bbae953eedaf74e9e,
title = "Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease",
abstract = "Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor-Ig (LTβR-Ig) inhibits the cytotoxic T lymphocyte (CTL) response to host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in a B6 to BDF1 mouse model. Here, we demonstrate that infusion of an mAb against CD40 ligand (CD40L) further increases the efficacy of LTβR-Ig, leading to complete prevention of GVHD. We further demonstrate that alloantigen-specific CTLs become anergic upon rapid expansion, and persist in the tolerized mice asa result of costimulatory blockade. Transfer of anergic CTLs to secondary F1 mice fails to induce GVHD despite the fact that anergic CTLs can be stimulated to proliferate in vitro by antigens and cytokines. Our study provides a potential new approach for the prevention of lethal GVHD.",
author = "Koji Tamada and Hideto Tamura and Dallas Flies and Fu, {Yang Xin} and Esteban Celis and Pease, {Larry R.} and Blazar, {Bruce R.} and Lieping Chen",
year = "2002",
month = "1",
day = "1",
doi = "10.1172/JCI0213604",
language = "English (US)",
volume = "109",
pages = "549--557",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease

AU - Tamada, Koji

AU - Tamura, Hideto

AU - Flies, Dallas

AU - Fu, Yang Xin

AU - Celis, Esteban

AU - Pease, Larry R.

AU - Blazar, Bruce R.

AU - Chen, Lieping

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor-Ig (LTβR-Ig) inhibits the cytotoxic T lymphocyte (CTL) response to host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in a B6 to BDF1 mouse model. Here, we demonstrate that infusion of an mAb against CD40 ligand (CD40L) further increases the efficacy of LTβR-Ig, leading to complete prevention of GVHD. We further demonstrate that alloantigen-specific CTLs become anergic upon rapid expansion, and persist in the tolerized mice asa result of costimulatory blockade. Transfer of anergic CTLs to secondary F1 mice fails to induce GVHD despite the fact that anergic CTLs can be stimulated to proliferate in vitro by antigens and cytokines. Our study provides a potential new approach for the prevention of lethal GVHD.

AB - Previous studies have shown that blockade of LIGHT, a T cell costimulatory molecule belonging to the TNF superfamily, by soluble lymphotoxin β receptor-Ig (LTβR-Ig) inhibits the cytotoxic T lymphocyte (CTL) response to host antigenic disparities and ameliorates lethal graft-versus-host disease (GVHD) in a B6 to BDF1 mouse model. Here, we demonstrate that infusion of an mAb against CD40 ligand (CD40L) further increases the efficacy of LTβR-Ig, leading to complete prevention of GVHD. We further demonstrate that alloantigen-specific CTLs become anergic upon rapid expansion, and persist in the tolerized mice asa result of costimulatory blockade. Transfer of anergic CTLs to secondary F1 mice fails to induce GVHD despite the fact that anergic CTLs can be stimulated to proliferate in vitro by antigens and cytokines. Our study provides a potential new approach for the prevention of lethal GVHD.

UR - http://www.scopus.com/inward/record.url?scp=85047686597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047686597&partnerID=8YFLogxK

U2 - 10.1172/JCI0213604

DO - 10.1172/JCI0213604

M3 - Article

VL - 109

SP - 549

EP - 557

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -